|Type||Buy / Hold / Sell|
|Year End 30th Jun||Unit||2019||2020||2021||2022||2023||2024E||2025E||CAGR / Avg|
|Diluted Normalised EPS|
|Op. Cashflow ps|
|Free Cashflow ps|
|Diluted Weighted Average Shares||m|
|Book Value ps|
Pro Medicus Limited is an Australia-based healthcare informatics company. The Company is a developer and supplier of healthcare imaging software and services to hospitals, diagnostic imaging groups and other related health entities in Australia, North America and Europe. The Company's products include Visage RIS, Visage RIS/PACS, Visage 7, Visage Ease Pro and Visage Ease. Its Visage RIS is a radiology information systems (RIS) medical software for practicing of management, training, installation and professional services. Visage RIS capabilities include patient registration, billing, scheduling, typing, HL7 integration, financial reporting, digital dictation and voice recognition integration. Its Visage 7.0 is a healthcare imaging software that provides radiologists and clinicians with visualization capability for rapidly viewing 2-D, 3-D and 4-D medical images and picture archive and communication system (PACS)/digital imaging software.
As of Today at 18:17 UTC, shares in Pro Medicus are trading at AU$88.06. This share price information is delayed by 15 minutes.
Shares in Pro Medicus last closed at AU$88.06 and the price had moved by +47.5% over the past 365 days. In terms of relative price strength the Pro Medicus share price has outperformed the ASX All Ordinaries Index by +52.68% over the past year.
The overall consensus recommendation for Pro Medicus is Hold. You can view the full broker recommendation list by unlocking its StockReport.
The Pro Medicus dividend yield is 0.34% based on the trailing twelve month period.
Last year, Pro Medicus paid a total dividend of AU$0.30, and it currently has a trailing dividend yield of 0.34%. We do not have any data on when Pro Medicus is to next pay dividends.
We do not have data on when Pro Medicus is to next pay dividends. The historic dividend yield on Pro Medicus shares is currently 0.34%.
To buy shares in Pro Medicus you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of AU$88.06, shares in Pro Medicus had a market capitalisation of AU$9.20bn.
Here are the trading details for Pro Medicus:
- Country of listing: Australia
- Exchange: ASX
- Ticker Symbol: PME
Based on an overall assessment of its quality, value and momentum Pro Medicus is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Pro Medicus is AU$80.08. That is 9.06% below the last closing price of AU$88.06.
Analysts covering Pro Medicus currently have a consensus Earnings Per Share (EPS) forecast of AU$0.77 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Pro Medicus. Over the past six months, its share price has outperformed the ASX All Ordinaries Index by +43.7%.
As of the last closing price of AU$88.06, shares in Pro Medicus were trading +26.08% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Pro Medicus PE ratio based on its reported earnings over the past 12 months is 101.79. The shares last closed at AU$88.06.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Pro Medicus' management team is headed by:
- Peter Kempen - NEC
- Sam Hupert - CEO
- Clayton Hatch - CFO
- Malte Westerhoff - CTO
- Brad Levin - GMG
- Danny Tauber - GMG
- Anthony Hall - EDR
- Teresa Gschwind - OTH
- Sean Lambright - OTH
- Leigh Farrell - NID
- Anthony Glenning - NID
- Deena Shiff - NID
- Alice Williams - NID